Ignite Creation Date:
2025-12-24 @ 2:15 PM
Ignite Modification Date:
2025-12-24 @ 2:15 PM
Study NCT ID:
NCT06998095
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-05-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-11-28
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-29
First Submit QC Date:
None
Study First Post Date:
2025-05-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-03
Last Update Post Date:
2025-12-09
Last Update Post Date Type:
ESTIMATED